Pharmacyclics Inc (PCYC) 100.49 $PCYC
Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory
1 Company Johnson & Johnson Should Buy
Brian Nichols, The Motley Fool - Motley Fool - Wed May 07, 1:30PM CDT
After a near 60% gain in the last two years, Johnson & Johnson is trading at 19 times trailing earnings, which compared to other big pharma peers is likely fair value. Therefore, finding value from this point is going to become more difficult,...
Pharmacyclics Down 30.3% Since SmarTrend Downtrend Call (PCYC)
Comtex SmarTrend(R) - Wed May 07, 11:04AM CDT
SmarTrend identified a Downtrend for Pharmacyclics (NASDAQ
CYC) on March 7th, 2014 at $133.00. In approximately 2 months, Pharmacyclics has returned 30.32% as of today's recent price of $92.68.
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
Biotech Stock Roundup: Endocyte Tumbles & Merrimack Soars on Pipeline News - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 07, 8:34AM CDT
Several companies reported earnings and provided regulatory and pipeline updates last week.
Stock Prices Updates, Study Results, Financial Results, and Share Repurchase Program - Analyst Notes on Gilead, Pfizer, Pharmacyclics, Intuitive Surgical and Mallinckrodt
PR Newswire - Wed May 07, 7:37AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc (NYSE: PFE), Pharmacyclics Inc. (NYSE: PCYC), Intuitive Surgical, Inc. (NASDAQ: ISRG) and Mallinckrodt plc (NYSE: MNK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2140-100free.
The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure
at The Street - Tue May 06, 9:00AM CDT
The F-R Rule is still 100% accurate predicting failure for oncology phase III studies undertaken by companies with market caps less than $300 million.
'Mad Money' Lightning Round: Valero Is Amazing
at The Street - Tue May 06, 5:00AM CDT
Cramer does not like Plug Power but he wants Old Republic International.
Why King Digital Entertainment, Intermune, and Pharmacyclics Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon May 05, 7:05PM CDT
This morning, it looked as though Monday would be a horrible day for the stock market, as worries about the health of China's economic growth and ongoing turmoil in Ukraine combined to send stocks falling at the open. Slowly but surely, though,...
Jim Cramer's 'Mad Money' Recap: Market Headwinds Getting Worse
at The Street - Mon May 05, 6:59PM CDT
Investors are just as likely to lose money as they are to make money on any given day, and there are a host of good reasons why, Cramer says.
1 Hot Biotech Stock + 1 Extremely Strange Call = 10% Plunge
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon May 05, 5:30PM CDT
Friday's bad market for Pharmacyclics wasn't the outcome of a poor quarter. In fact, just looking at the 1st quarter sales of Imbruvica, the blood cancer drug it shares with Johnson & Johnson , there is no reason to think it won't fulfill...
Nasdaq stocks posting largest percentage increases
AP - Mon May 05, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Earnings Beat at Pharmacyclics, Guidance Pulls Down Stock - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 10:30AM CDT
Pharmacyclics' (PCYC) first quarter earnings of 23 cents per share blew past the Zacks Consensus Estimate of 9 cents per share.
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
Kevin Cook - Zacks Investment Research - Mon May 05, 1:49AM CDT
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
Today's 3 Biotech Blow-Ups
Todd Campbell, The Motley Fool - Motley Fool - Fri May 02, 1:40PM CDT
While the Motley Fool believes investing should be a long term affair, investors should be aware when companies of interest make big moves higher or lower. Such big moves are usually due to important developments that could significantly influence...
Why Pharmacyclics, Inc. Shares Stumbled Out of the Gate
Sean Williams, The Motley Fool - Motley Fool - Fri May 02, 1:19PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Pharmacyclics , a biopharmaceutical...
Pharmacyclics Reports First Quarter 2014 Results
PR Newswire - Fri May 02, 7:00AM CDT
Pharmacyclics, Inc. (the "Company"
(Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended March 31, 2014.
Pharmacyclics Shares Down 29.0% Since SmarTrend's Sell Call (PCYC)
Comtex SmarTrend(R) - Wed Apr 30, 9:42AM CDT
SmarTrend identified a Downtrend for Pharmacyclics (NASDAQ CYC) on March 7th, 2014 at $133.00. In approximately 2 months, Pharmacyclics has returned 29.04% as of today's recent price of $94.38.
Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory
1 Company Johnson & Johnson Should Buy
Brian Nichols, The Motley Fool - Motley Fool - Wed May 07, 1:30PM CDT
After a near 60% gain in the last two years, Johnson & Johnson is trading at 19 times trailing earnings, which compared to other big pharma peers is likely fair value. Therefore, finding value from this point is going to become more difficult,...
Pharmacyclics Down 30.3% Since SmarTrend Downtrend Call (PCYC)
Comtex SmarTrend(R) - Wed May 07, 11:04AM CDT
SmarTrend identified a Downtrend for Pharmacyclics (NASDAQ
CYC) on March 7th, 2014 at $133.00. In approximately 2 months, Pharmacyclics has returned 30.32% as of today's recent price of $92.68. Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
Biotech Stock Roundup: Endocyte Tumbles & Merrimack Soars on Pipeline News - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 07, 8:34AM CDT
Several companies reported earnings and provided regulatory and pipeline updates last week.
Stock Prices Updates, Study Results, Financial Results, and Share Repurchase Program - Analyst Notes on Gilead, Pfizer, Pharmacyclics, Intuitive Surgical and Mallinckrodt
PR Newswire - Wed May 07, 7:37AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc (NYSE: PFE), Pharmacyclics Inc. (NYSE: PCYC), Intuitive Surgical, Inc. (NASDAQ: ISRG) and Mallinckrodt plc (NYSE: MNK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2140-100free.
The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure
at The Street - Tue May 06, 9:00AM CDT
The F-R Rule is still 100% accurate predicting failure for oncology phase III studies undertaken by companies with market caps less than $300 million.
'Mad Money' Lightning Round: Valero Is Amazing
at The Street - Tue May 06, 5:00AM CDT
Cramer does not like Plug Power but he wants Old Republic International.
Why King Digital Entertainment, Intermune, and Pharmacyclics Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon May 05, 7:05PM CDT
This morning, it looked as though Monday would be a horrible day for the stock market, as worries about the health of China's economic growth and ongoing turmoil in Ukraine combined to send stocks falling at the open. Slowly but surely, though,...
Jim Cramer's 'Mad Money' Recap: Market Headwinds Getting Worse
at The Street - Mon May 05, 6:59PM CDT
Investors are just as likely to lose money as they are to make money on any given day, and there are a host of good reasons why, Cramer says.
1 Hot Biotech Stock + 1 Extremely Strange Call = 10% Plunge
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon May 05, 5:30PM CDT
Friday's bad market for Pharmacyclics wasn't the outcome of a poor quarter. In fact, just looking at the 1st quarter sales of Imbruvica, the blood cancer drug it shares with Johnson & Johnson , there is no reason to think it won't fulfill...
Nasdaq stocks posting largest percentage increases
AP - Mon May 05, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Earnings Beat at Pharmacyclics, Guidance Pulls Down Stock - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 10:30AM CDT
Pharmacyclics' (PCYC) first quarter earnings of 23 cents per share blew past the Zacks Consensus Estimate of 9 cents per share.
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
Kevin Cook - Zacks Investment Research - Mon May 05, 1:49AM CDT
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
Today's 3 Biotech Blow-Ups
Todd Campbell, The Motley Fool - Motley Fool - Fri May 02, 1:40PM CDT
While the Motley Fool believes investing should be a long term affair, investors should be aware when companies of interest make big moves higher or lower. Such big moves are usually due to important developments that could significantly influence...
Why Pharmacyclics, Inc. Shares Stumbled Out of the Gate
Sean Williams, The Motley Fool - Motley Fool - Fri May 02, 1:19PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Pharmacyclics , a biopharmaceutical...
Pharmacyclics Reports First Quarter 2014 Results
PR Newswire - Fri May 02, 7:00AM CDT
Pharmacyclics, Inc. (the "Company"
(Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended March 31, 2014. Pharmacyclics Shares Down 29.0% Since SmarTrend's Sell Call (PCYC)
Comtex SmarTrend(R) - Wed Apr 30, 9:42AM CDT
SmarTrend identified a Downtrend for Pharmacyclics (NASDAQ
CYC) on March 7th, 2014 at $133.00. In approximately 2 months, Pharmacyclics has returned 29.04% as of today's recent price of $94.38. 
